Connect with us

E-Business

Elon Musk Says First Human Implanted with Neuralink Brain Chip now Moves a ‘Mouse around Screen just by Thinking’

Published

on

Kindly share this post

Elon Musk, founder of Neuralink Corp. an American neurotechnology company, has said that the first human patient implanted with a brain chip from Neuralink appears to have fully recovered and is able to control a computer mouse using his thoughts.

Elon Musk Says First Human Implanted with Neuralink Brain Chip now Moves a 'Mouse around Screen just by Thinking'

Elon Musk

Musk and a team of seven scientists and engineers, founded Neuralink in 2016 and was first publicly reported in March 2017.

It is developing implantable brain–computer interfaces, based in Fremont, California, as of 2024.

‘Progress is good and the patient seems to have made a full recovery, with neural effects that we are aware of,‘ Musk said in a Spaces event on X (Twitter).

‘Patient is able to move a mouse around the screen by just thinking.’

Musk said Neuralink is now trying to get as many mouse button clicks as possible from the patient.

Neuralink successfully implanted the ‘Telepathy’ chip on the patient last month, after receiving approval for human trial recruitment in September.

The identity of the first Neuralink patient is still unclear, however; MailOnline has contacted the firm for more information.

Neuralink’s tech uses a robot to surgically place a brain-computer interface implant in a region of the brain that controls the intention to move.

The system consists of a computer chip attached to tiny flexible threads stitched into the brain by a ‘sewing-machine-like’ robot.

The robot removes a small chunk of the skull, connects the thread-like electrodes to certain areas of the brain, stitches up the hole and the only visible remains is a scar left behind from the incision.

Musk said that this procedure takes just 30 minutes, does not require general anaesthesia, and patients will be able to return home on the same day.

It’s unclear if all these promises apply to the first patient to receive the implant, although Musk said he or she is ‘recovering well’.

But after Neuralink’s early trials saw 1,500 animals killed during rushed experiments, experts have raised serious concerns about the implant’s safety.

Speaking to MailOnline, Dr Dean Burnett, honorary research associate at Cardiff University, called the human trials ‘disconcerting and alarming.’

‘The speed at which [Musk] has gone from having no involvement in neurosurgical implants to making massive global statements is disconcerting and alarming,’ he said.

The company’s initial goal is to let people control a computer cursor or keyboard using their thoughts and communicate wirelessly with the world – like ‘replacing a piece of the skull with a smartwatch’, Musk has said.

It would enable us to share our thoughts, fears, hopes and anxieties without demeaning ourselves with written or spoken language, the firm claims.

But it could also help paralysed people walk again and cure other neurological ailments.

Musk has also said that he’d be comfortable implanting a brain chip into one of his children, in response to a query.

‘I would say we’re at the point where at least, in my opinion, it would not be dangerous,’ he said.

Implanting ‘Telepathy’ in a human is part of Neuralink’s PRIME study, a trial to evaluate the safety of the implant and the surgical robot that does the procedure.

Musk has grand ambitions for Neuralink, saying it would facilitate speedy surgical insertions of its chip devices to treat conditions like obesity, autism, depression, and schizophrenia.

However, Neuralink, which was valued at about $5 billion last year, has faced repeated calls for scrutiny regarding its safety protocols and animal testing.

Neuralink has spent the past few years testing the implant on animals, which has given mixed results.

In a 2020 presentation, Musk unveiled the Neuralink chip to the public for the very first time, with a demonstration on a pig named Gertrude

Gertrude’s brain signals were visualised in real-time while she snuffled around her pen, that were being picked up by her implant.

Another pig involved in the demonstration had once had an implant but then had it removed and was living a ‘healthy life’.

The following year, Musk did another demonstration, which involved a macaque monkey with a brain chip that played a computer game by thinking alone.

However, in February 2022, Neuralink confirmed that monkeys had died during its tests, although denied any animal abuse.

The latter was in response to claims made by a non-profit the Physicians Committee for Responsible Medicine (PCRM) in a complaint with the US Department of Agriculture.

Concerns raised by PCRM in the complaint included an example of a monkey missing fingers and toes that may have been lost to ‘self mutilation’.

Whether you love him or hate him, Elon Musk is the mastermind behind some of the most ingenuous technology projects of the modern era.

The billionaire entrepreneur is the boss of carmaker Tesla, private space firm SpaceX and brain-computer interface startup Neuralink, among others.

 

 

 

 

 


Kindly share this post

Nigeria CommunicationsWeek believes that technology makes life more exciting and helps improve the lives of people around Nigeria and indeed the world. So since 2007, we have devoted our energy to independent reportage of technology and how they affect lives.

E-Business

SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa

Published

on

Kindly share this post

SOPHiA GENETICS, a cloud-native software company in the healthcare space and a leader in data-driven medicine, has announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™.

Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent.

The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale.

There are roughly 1 million new cancer patients each year in Africa and currently, comprehensive genomic profiling and liquid biopsy testing options are not widely available.

This means that patients are forced to forego this testing or travel out of continent for these testing options. Syndicate Bio’s implementation of this new offering will provide cutting-edge liquid biopsy testing to many of these patients and will help progress the company’s goal of advancing genomics and precision medicine in an area of the world that has been historically underserved in these areas.

“Partnering with SOPHiA Genetics to bring MSK-ACCESS® powered with SOPHiA DDM™ to our lab is a monumental step in accelerating the cancer treatment and research landscape across Africa, beginning in Nigeria. Next-generation sequencing technologies in oncology and liquid biopsy, which this collaboration enables, hold the potential for creating a leapfrogging opportunity in the oncology treatment and research landscape in Africa,” said Abasi Ene-Obong, PhD., Founder, Syndicate Bio.

“Through this collaboration, we aim to enable the widespread application of precision medicine in oncology across Africa, and thus contributing to the improvement of patient outcomes across the African continent.

“We believe our scientific expertise, combined with AI-enabled technologies and data-driven solutions enabled by SOPHiA GENETICS, presents a unique opportunity to fundamentally transform the journey of cancer patients through non-invasive cancer analysis, predictive genetic testing, and effective precision medicine.”

Syndicate Bio is driving genomics and precision medicine initiatives across the world’s most diverse regions through large-scale partnerships with governments, industry, and other stakeholders. Through its work, Syndicate Bio is making local impact while accelerating drug discovery and development.

By focusing on Africa, Syndicate Bio is poised to make a significant impact, starting with Nigeria, by introducing its pioneering clinical oncology offerings in an underserved region.

Through this endeavor, Syndicate Bio aims to improve cancer diagnosis and treatment for African patients. This initiative not only facilitates local next-generation sequencing (NGS) testing and liquid biopsy testing but also extends access to clinical trial participation, empowering patients and healthcare providers alike.

MSK-ACCESS® powered with SOPHiA DDM™  is a decentralized version of a highly validated ctDNA test developed by MSK that involves the deep sequencing of 146 key cancer-associated genes, and will augment Syndicate Bio’s tumor profiling capabilities, allowing them to utilize a small blood sample to generate a comprehensive report in an efficient and expedited time frame.

The use of liquid biopsy is less invasive than traditional biopsy, and can help simplify patient monitoring, whilst driving the uptake of precision medicine.

The offering combines the sophisticated analytics, state-of-the-art algorithms, and decentralized, cloud-based offerings of the SOPHiA DDM™ Platform, with the scientific and clinical expertise of MSK in cancer genomics to provide a best-in-class liquid biopsy solution.

“In our mission to democratize data-driven medicine, our decentralized global network and unique set of partnerships enable us to help reach underserved populations, just as those that are served by Syndicate Bio,” said Philippe Menu, MD, PhD., Chief Medical Officer, SOPHiA GENETICS.

“By implementing this solution, Syndicate Bio will make a measurable impact throughout Africa, while also helping to generate an unparalleled and comprehensive dataset and provide invaluable insights and knowledge to shape the future of global healthcare.”

In late 2023, SOPHiA GENETICS and MSK announced they are working in partnership with AstraZeneca to bring the world-class MSK-ACCESS® powered with SOPHiA DDM™ testing solution to countries and regions around the globe, including underserved areas where access to testing remains scarce.


Kindly share this post
Continue Reading

E-Business

Abdullahi, NITDA Boss Harps on Partnership to Drive Advance Digital Transformation Agenda

Published

on

Kindly share this post

Mallam Kashifu Abdullahi, director-general, National Information Technology Development Agency (NITDA), has reaffirmed the importance of collaboration in advancing Nigeria’s digital transformation agenda.

Abdullahi, NITDA Boss Harps on Partnership to Drive Advance Digital Transformation Agenda

L-R: Mallam Kashifu Abdullahi,  director-general, National Information Technology Development Agency, with Brig. Gen., Abdulrahman Idris, team lead of the Senior Executive Course 46 2024, National Institute for Policy and Strategic Studies, Kuru, Jos during a strategic tour visit to the agency headquarters in Abuja.

Abdullahi disclosed this during a strategic engagement with participants of the 2024 Senior Executive Course 46 from the National Institute for Policy and Strategic Studies (NIPSS), a delegation led by Brigadier General Abdulrahman Idris.

Abdullahi emphasised that no organisation can achieve its goals in isolation, stressing the need for collaborative efforts to harness ideas, experiences and insights for national development. He highlighted the potential of collaboration between NITDA and NIPSS to leverage technology and digital innovation for driving economic growth, creating job opportunities and attracting foreign direct investment (FDI).

“At NITDA, we have re-imagined our social contract with Nigerians, focusing on improving service delivery and fostering the swift growth of the ICT sector,” said Abdullahi. He emphasised the agency’s commitment to serving Nigerians and outlined the strategic direction outlined in NITDA’s Strategic Roadmap and Action Plan (SRAP 2024-2027) 2.0. The SRAP is structured around eight pillars aimed at fostering digital literacy, building a robust technology research ecosystem, strengthening policy implementation, promoting inclusive access to digital infrastructure, enhancing cybersecurity, nurturing innovation and entrepreneurship, forging partnerships and cultivating a vibrant organisational culture.

The brigadier-general provided insights into NIPSS’s role as Nigeria’s foremost policy think-tank, tasked with developing top-class technocrats to drive national development initiatives. He highlighted NIPSS’s contributions to policy formulation and implementation over the years, emphasising the institution’s mandate to address issues of national interest, particularly in the digital economy sector.

The collaboration between NITDA and NIPSS underscores the importance of synergistic efforts in harnessing technology and innovation for national development. By leveraging each other’s expertise and resources, both organisations aim to drive economic growth, foster job creation, and position Nigeria as a leading player in the global digital economy.

Through strategic partnerships and collaborative initiatives, NITDA and NIPSS are poised to chart a path towards sustainable development, leveraging digital innovation as a catalyst for socioeconomic transformation and inclusive growth.

 


Kindly share this post
Continue Reading

E-Business

IvoryPay, Tether to Drive Crypto Transfers Across Africa

Published

on

Kindly share this post

Ivorypay, a blockchain-based payment and remittance firm, has teamed with Tether, the stablecoin pioneer, to improve crypto-based transactions across Africa.

Tether is the business that developed the stablecoin, USDT, and with this agreement, it will mint and issue USDT straight to IvoryPay.

According to the partners, this agreement would provide more dependable and economical digital transaction choices to businesses and consumers across Africa.

Ivorypay will leverage Tether’s widespread acceptance to provide a buffer against the typically unpredictable nature of crypto-currencies, increasing user confidence in using digital currencies for daily transactions as well as cross-border transfers.

“Partnering with Tether is a strategic move that aligns perfectly with our vision of simplifying and securing crypto transactions across Africa,” said Oluwatobi Ajayi, CEO, IvoryPay.

He added: “It gives us easy access to the liquidity we need to cater to more businesses and individuals across the continent and to do that cheaper and faster than anybody else, which we believe will significantly enhance user trust and increase adoption rates across our platforms.”

“This strategic partnership between Ivorypay and Tether represents a transformative step for digital transactions across Africa,” said Aly Madhavji, managing partner of Blockchain Founders Fund.

“By incorporating USDT into their payment systems, IvoryPay aims to increase financial inclusion and streamline cross-border remittances, establishing a new standard for stability and efficiency in the region’s financial services We are thrilled to assist Ivorypay as they endeavour to create new opportunities for businesses and consumers across Africa.”


Kindly share this post
Continue Reading

Trending